Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2019

View Archived Issues

Size matters in RNA-seq analyses

Anti-Siglec-15 monoclonal antibody NC-318 well tolerated and active in first-in-human study

IND approval and patent application for the first-ever liquid formulation of topiramate

Results presented from ongoing phase I/II study of IDE-196

ZGN-1345 demonstrates promise in preclinical models of NASH and HCC

Phase II data presented for ziltivekimab in hemodialysis patients

SARA as a potential new therapeutic target in human chronic kidney disease

New FFA1 agonist derived from an old scaffold shows potential for treatment of type 2 diabetes

Gut microbiota dysbiosis promotes neuroinflammation in Alzheimer's disease progression

Discovery of new potent NS4B inhibitor, JMX-0254

Rat homologue of FX-201 decreases incidence and severity of osteoarthritis-related lesions

TLN1 gene mutations linked to human nephrotic syndrome

Redox repositioning reaps benefits in TB treatment

Truncated ACE2 fusion protein targets RAS overactivity in renal diseases

Data on peripheral immune responses to selgantolimod from phase II study in HBV reported

L-FABP levels correlated with sarcopenia measures in diabetic kidney disease

Eternity Bioscience patents RORC antagonists

Bristol-Myers Squibb discloses new UFO and MERTK inhibitors

Rigel Pharmaceuticals synthesizes RIPK1 inhibitors

Enanta Pharmaceuticals describes new MAP3K5 inhibitors

Kinnate Biopharma patents CDK inhibitors

FDA approves Givlaari for acute hepatic porphyria

New phase I study evaluates bispecific PSMAxCD3 antibody CC-1 in CRPC

Arcutis begins phase II study of ARQ-154 foam for seborrheic dermatitis

Phoenix Molecular initiates first-in-human study of PMD-026 in advanced breast cancer

FDA approves phase I/II trial of Hope's adipose-derived mesenchymal stem cells for Alzheimer's

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...